VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2022 | The potential of early treatment of SMM with immunotherapy

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of early treatment with CAR-T therapy or bispecific antibodies for patients with smoldering multiple myeloma (SMM), highlighting remaining questions in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Sognef: Honoraria; Bristol Myers Squibb: Honoraria; GSK: Honoraria; Huron Consulting: Honoraria; Veeva Systems: Honoraria; Vor Biopharma: Honoraria; Aptitude Health: Honoraria; Sanofi: Honoraria; Menarini Silicon Biosystems: Honoraria; Window Therapeutics: Other: Advisory board participation; The Binding Site: Honoraria; Takeda: Honoraria; Pfizer: Honoraria; Oncopeptides: Honoraria; Janssen: Honoraria; Amgen: Honoraria; Adaptive: Honoraria; AbbVie: Honoraria; Novartis: Research Funding; Celgene: Research Funding.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter